Journal of Gastroenterology

, Volume 41, Issue 5, pp 401–407 | Cite as

DNA methylation as a marker for the past and future

  • Toshikazu Ushijima
  • Takeshi Nakajima
  • Takao Maekita
Review

Abstract

Aberrant methylation of CpG islands in promoter regions can permanently inactivate tumor-suppressor genes, as mutations and chromosomal abnormalities do. In gastric cancers, CDKN2A, CDH1, and MLH1 are inactivated more frequently by aberrant methylation than by mutations, and novel tumor-suppressor genes inactivated by promoter methylation are being identified. We recently found that Helicobacter pylori (HP), a potent gastric carcinogen, induces aberrant methylation in gastric mucosae. When a panel of CpG islands was examined, some CpG islands were consistently methylated in gastric mucosae of individuals with HP infection, while others were resistant. The amount of methylated DNA molecules in the gastric mucosae (methylation level) fluctuated while active HP infection was present, but decreased after it was no longer present. Among individuals without active HP infection, methylation levels in the gastric mucosae were higher in individuals with gastric cancers than in those without. DNA methylation is emerging as a promising marker for past exposure to carcinogens and future risk of cancers.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jones, PA, Baylin, SB 2002The fundamental role of epigenetic events in cancerNat Rev Genet341528PubMedCrossRefGoogle Scholar
  2. 2.
    Riggs, AD, Xiong, Z 2004Methylation and epigenetic fidelityProc Natl Acad Sci U S A10145PubMedCrossRefGoogle Scholar
  3. 3.
    Ushijima, T, Watanabe, N, Okochi, E, Kaneda, A, Sugimura, T, Miyamoto, K 2003Fidelity of the methylation pattern and its variation in the genomeGenome Res1386874PubMedCrossRefGoogle Scholar
  4. 4.
    Ushijima, T 2005Detection and interpretation of altered methylation patterns in cancer cellsNat Rev Cancer522331PubMedCrossRefGoogle Scholar
  5. 5.
    Robertson, KD 2005DNA methylation and human diseaseNat Rev Genet6597610PubMedCrossRefGoogle Scholar
  6. 6.
    Ushijima, T, Sasako, M 2004Focus on gastric cancerCancer Cell51215PubMedCrossRefGoogle Scholar
  7. 7.
    Baylin, SB, Ohm, JE 2006Epigenetic gene silencing in cancer—a mechanism for early oncogenic pathway addiction?Nat Rev Cancer610716PubMedCrossRefGoogle Scholar
  8. 8.
    Laird, PW 2003The power and the promise of DNA methylation markersNat Rev Cancer325366PubMedCrossRefGoogle Scholar
  9. 9.
    Miyamoto, K, Ushijima, T 2005Diagnostic and therapeutic applications of epigeneticsJpn J Clin Oncol35293301PubMedCrossRefGoogle Scholar
  10. 10.
    Egger, G, Liang, G, Aparicio, A, Jones, PA 2004Epigenetics in human disease and prospects for epigenetic therapyNature42945763PubMedCrossRefGoogle Scholar
  11. 11.
    Li, QL, Ito, K, Sakakura, C, Fukamachi, H, Inoue, K, Chi, XZ,  et al. 2002Causal relationship between the loss of RUNX3 expression and gastric cancerCell10911324PubMedCrossRefGoogle Scholar
  12. 12.
    Yamashita, S, Tsujino, Y, Moriguchi, K, Tatematsu, M, Ushijima, T 2006Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2′-deoxycytidine treatment and oligonucleotide microarrayCancer Sci976471PubMedCrossRefGoogle Scholar
  13. 13.
    Song, JZ, Stirzaker, C, Harrison, J, Melki, JR, Clark, SJ 2002Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cellsOncogene21104861PubMedCrossRefGoogle Scholar
  14. 14.
    Ushijima, T, Okochi-Takada, E 2005Aberrant methylations in cancer cells: where do they come from?Cancer Sci9620611PubMedCrossRefGoogle Scholar
  15. 15.
    Kaneda, A, Wakazono, K, Tsukamoto, T, Watanabe, N, Yagi, Y, Tatematsu, M,  et al. 2004Lysyl oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancersCancer Res6464105PubMedCrossRefGoogle Scholar
  16. 16.
    Furuta J, Nobeyama Y, Umebayashi Y, Otsuka F, Kikuchi K, Ushijima T. Silencing of peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas. Cancer Res (in press)Google Scholar
  17. 17.
    Yoshikawa, H, Matsubara, K, Qian, GS, Jackson, P, Groopman, JD, Manning, JE,  et al. 2001SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activityNat Genet282935PubMedCrossRefGoogle Scholar
  18. 18.
    Suzuki, H, Watkins, DN, Jair, KW, Schuebel, KE, Markowitz, SD, Chen, WD,  et al. 2004Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancerNat Genet3641722PubMedCrossRefGoogle Scholar
  19. 19.
    Sato, N, Fukushima, N, Chang, R, Matsubayashi, H, Goggins, M 2006Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancersGastroenterology13054865PubMedCrossRefGoogle Scholar
  20. 20.
    Issa, JP, Ottaviano, YL, Celano, P, Hamilton, SR, Davidson, NE, Baylin, SB 1994Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colonNat Genet753640PubMedCrossRefGoogle Scholar
  21. 21.
    Hsieh, CJ, Klump, B, Holzmann, K, Borchard, F, Gregor, M, Porschen, R 1998Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitisCancer Res5839425PubMedGoogle Scholar
  22. 22.
    Kondo, Y, Kanai, Y, Sakamoto, M, Mizokami, M, Ueda, R, Hirohashi, S 2000Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis—a comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinomaHepatology329709PubMedCrossRefGoogle Scholar
  23. 23.
    Maekita, T, Nakazawa, K, Mihara, M, Nakajima, T, Yanaoka, K, Iguchi, M,  et al. 2006High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer riskClin Cancer Res1298995PubMedCrossRefGoogle Scholar
  24. 24.
    El-Omar, EM, Carrington, M, Chow, WH, McColl, KE, Bream, JH, Young, HA,  et al. 2000Interleukin-1 polymorphisms associated with increased risk of gastric cancerNature404398402PubMedCrossRefGoogle Scholar
  25. 25.
    Lee, KA, Ki, CS, Kim, HJ, Sohn, KM, Kim, JW, Kang, WK,  et al. 2004Novel interleukin 1beta polymorphism increased the risk of gastric cancer in a Korean populationJ Gastroenterol3942933PubMedCrossRefGoogle Scholar
  26. 26.
    Chiba, T, Seno, H, Marusawa, H, Wakatsuki, Y, Okazaki, K 2006Host factors are important in determining clinical outcomes of Helicobacter pylori infectionJ Gastroenterol4119PubMedCrossRefGoogle Scholar
  27. 27.
    Nakajima, T, Oda, I, Gotoda, T, Hamanaka, H, Eguchi, T, Yokoi, C,  et al. 2006Metachronous gastric cancers after endoscopic resection: how effective is annual endoscopic surveillance?Gastric Cancer9938PubMedCrossRefGoogle Scholar
  28. 28.
    Issa, JP, Ahuja, N, Toyota, M, Bronner, MP, Brentnall, TA 2001Accelerated age-related CpG island methylation in ulcerative colitisCancer Res6135737PubMedGoogle Scholar
  29. 29.
    Kantarjian, H, Issa, JP, Rosenfeld, CS, Bennett, JM, Albitar, M, DiPersio, J,  et al. 2006Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized studyCancer1061794803PubMedCrossRefGoogle Scholar
  30. 30.
    Abe, M, Ohira, M, Kaneda, A, Yagi, Y, Yamamoto, S, Kitano, Y,  et al. 2005CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomasCancer Res6582834PubMedGoogle Scholar
  31. 31.
    Abe M, Westermann F, Nakagawara A, Takato T, Schwab M, Ushijima T. Marked and independent prognostic significance of the CpG island methylator phenotype in neuroblastomas. Cancer Lett (in press)Google Scholar

Copyright information

© Springer-Verlag Tokyo 2006

Authors and Affiliations

  • Toshikazu Ushijima
    • 1
  • Takeshi Nakajima
    • 1
  • Takao Maekita
    • 1
  1. 1.Carcinogenesis DivisionNational Cancer Center Research InstituteTokyoJapan

Personalised recommendations